{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:40:27Z","timestamp":1794490827823,"version":"4.9.1"},"reference-count":62,"publisher":"Informa UK Limited","issue":"3-4","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.1080\/21678421.2025.2604233","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T19:50:42Z","timestamp":1766433042000},"page":"285-300","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Patient experience and clinical outcome assessment validity in amyotrophic lateral sclerosis: a targeted literature review"],"prefix":"10.1080","volume":"27","author":[{"given":"Sarah E.","family":"Curtis","sequence":"first","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophi","family":"Tatlock","sequence":"additional","affiliation":[{"name":"Adelphi Values, Patient-Centered Outcomes","place":["Bollington, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"O\u2019Hara","sequence":"additional","affiliation":[{"name":"Adelphi Values, Patient-Centered Outcomes","place":["Bollington, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekin","family":"Se\u00e7inti","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole F.","family":"Mehdiyoun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Ayala-Nunes","sequence":"additional","affiliation":[{"name":"Adelphi Values, Patient-Centered Outcomes","place":["Bollington, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[{"name":"Adelphi Values, Patient-Centered Outcomes","place":["Bollington, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Fernelius","sequence":"additional","affiliation":[{"name":"Adelphi Values, Patient-Centered Outcomes","place":["Bollington, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Hodson","sequence":"additional","affiliation":[{"name":"Adelphi Values, Patient-Centered Outcomes","place":["Bollington, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Delbecque","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000730"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14393"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26801"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12111523"},{"key":"e_1_3_6_6_1","unstructured":"Medical Professionals Reference. ALS treatment relyvrio to be removed from the market. 2024. https:\/\/www.empr.com\/home\/news\/als-treatment-relyvrio-to-be-removed-from-the-market\/#:\u223c:text=The%20Company%20has%20decided%20to the%20phase%203%20PHOENIX%20trial. Accessed 1 May 2024."},{"key":"e_1_3_6_7_1","first-page":"CD001447","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"2012","author":"Miller RG","year":"2012","unstructured":"Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012:CD001447.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00068"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab242"},{"key":"e_1_3_6_10_1","unstructured":"US Food and Drug Administration. Accelerating access to critical therapies for ALS act \u2013 ACT for ALS. 2023. https:\/\/www.fda.gov\/news-events\/public-health-focus\/accelerating-access-critical-therapies-als-act-act-als. Accessed 29 July 2023."},{"key":"e_1_3_6_11_1","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers EndpointS and other Tools) Resource [Internet] Silver Spring (MD): Food and Drug Administration (US). Co-published by National Institutes of Health (US) Bethesda (MD). 2016 [Updated 2021 Nov 29]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK338448\/."},{"key":"e_1_3_6_12_1","unstructured":"European Medicines Agency. EMA reflection paper on the regulatory guidance for the use of Health-Related Quality of Life (HRQOL) measures in the evaluation of medicinal products. https:\/\/www.ema.europa.eu\/en\/regulatory-guidance-use-health-related-quality-life-hrql-measures-evaluation-medicinal-products-scientific-guideline. 2005."},{"key":"e_1_3_6_13_1","unstructured":"US Food and Drug Administration. US Department of Health and Human Services. Food and Drug Administration. Guidance for industry: Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed February 28 2017."},{"key":"e_1_3_6_14_1","unstructured":"US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. 2018. https:\/\/www.fda.gov\/media\/139088\/download. Accessed 1 November 2023."},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-022-00607-6"},{"key":"e_1_3_6_16_1","unstructured":"US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. 2022. https:\/\/www.fda.gov\/media\/131230\/download. Accessed 1 November 2023."},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.013"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.014"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.11.005"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2024.2322539"},{"key":"e_1_3_6_21_1","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf Accessed 1 November 2023."},{"key":"e_1_3_6_22_1","unstructured":"US Food and Drug Administration. Amyotrophic lateral sclerosis: developing drugs for treatment guidance for industry. 2019. https:\/\/www.fda.gov\/media\/130964\/download. Accessed 1 November 2023."},{"key":"e_1_3_6_23_1","unstructured":"US Food and Drug Administration. Patient-focused drug development: Selecting developing or modifying fit-for-purpose clinical outcome assessments. Guidance for industry food and drug administration staff and other stakeholders. 2025. https:\/\/www.fda.gov\/media\/159500\/download. Accessed 11 November 2025."},{"key":"e_1_3_6_24_1","unstructured":"Arteaga-Bracho E Kelley Erb M Paradis AD Cochrane T Zajac L Hagenacker T et al. editors. Exploring the content validity of KonectomTM NMD Digital Outcome Assessments: Perspectives of Adults Living with SMA and ALS. MDA Conference; 2022; Nashville TN."},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002741"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.14003"},{"key":"e_1_3_6_27_1","unstructured":"US Food and Drug Administration. Pre-diagnosis genetic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD). 2023. https:\/\/www.fda.gov\/patients\/learn-about-fda-patient-engagement\/patient-listening-session-summaries. Accessed 9 September 2023."},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01551-5"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200537"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909119834493"},{"key":"e_1_3_6_31_1","unstructured":"The ALS Association. The voice of the patient for amyotrophic lateral sclerosis; ALS patient-focused drug development survey October-November 2017. Version Date: October 24 2019 https:\/\/www.als.org\/sites\/default\/files\/2020-06\/VOP-ALS_FINAL_For-Posting-10-23-19.pdf"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.15697"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101768"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0301249"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-93270-4"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/09638288.2025.2555973"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/02692163241242320"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-082398"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(99)00210-5"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.09452"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000238505.22066.fc"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02434.x"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.3109\/17482961003727954"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2016.1248976"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(97)00239-6"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10423-x"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057584"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2023.2260832"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03161085"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/146608299300080022"},{"key":"e_1_3_6_51_1","unstructured":"Simmons Z. The ALS Specific Quality of Life-Revised (ALSSQOL-R) user\u2019s guide. Available here: https:\/\/www.pennstatehealth.org\/sites\/default\/files\/Neurology\/ALSSQOL-%20Manual.pdf. Accessed 1 November 2023."},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2013.805784"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2023.2204871"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-018-0056-3"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2025.2469721"},{"key":"e_1_3_6_56_1","first-page":"e088","article-title":"Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults","volume":"2","author":"Delgado DA","year":"2018","unstructured":"Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, et al. Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults. J Am Acad Orthop Surg Glob Res Rev. 2018;2:e088.","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61156-7"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209549"},{"key":"e_1_3_6_59_1","unstructured":"International Alliance of ALS\/MND Associations (IAAMA). Optimizing Clinical trials: outcome measures for ALS\/MND; Roundtable. 2022. https:\/\/www.als-mnd.org\/wp-content\/uploads\/2022\/06\/International-Alliance-of-ALS-MND-Associations-Regulatory-Pathways-Roundtable-Report-.pdf. Accessed 1 November 2023."},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2013.817585"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.2715"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-022-01919-9"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-023-03377-2"}],"container-title":["Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21678421.2025.2604233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/21678421.2025.2604233","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21678421.2025.2604233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:36:58Z","timestamp":1790422618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21678421.2025.2604233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":62,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.1080\/21678421.2025.2604233"],"URL":"https:\/\/doi.org\/10.1080\/21678421.2025.2604233","relation":{},"ISSN":["2167-8421","2167-9223"],"issn-type":[{"value":"2167-8421","type":"print"},{"value":"2167-9223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iafd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iafd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}